Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABBV-637 or ABBV-155 + ERAS-801 in EGFR-Amplified Glioblastoma
NCT06934889Phase 1Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Apr 2025
- Primary completion
- Apr 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of ABBV-637 and mirzotamab clezutoclax in glioblastoma (GBM) and Gliosarcoma (GS) (4 cohorts), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Dose Limiting Toxicity at 1 year. Started Apr 2025; status: recruiting.
02
Drugs
ABBV-637mirzotamab clezutoclax
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT06934889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06934889.